Leerink Partners Maintains Outperform on Definium Therapeutics, Raises Price Target to $52

Benzinga Newsdesk www.benzinga.com Positive 91.6%

Neg 0% Neu 0% Pos 91.6%

Leerink Partners analyst Marc Goodman maintains Definium Therapeutics (NASDAQ:DFTX) with a Outperform and raises the price target from $30 to $52.